GPR55
GPR55 is a lysophosphatidylinositols and cannabinoids receptor. It is involved in various signaling cascade and plays a role in neuropathic/inflammatory pain, cancer and metabolic regulation etc.
Products for GPR55
- Cat.No. Product Name Information
- GC12728 Abn-CBD GPR55 cannabinoid receptor agonist
- GC35339 Anandamide An immune modulator in the central nervous system
- GC35694 CID 16020046 CID 16020046 is a potent and selective GPR55 antagonist and inhibits GPR55 constitutive activity with an IC50 of 0.15 μM. CID 16020046 inhibits GPR55-mediated Ca2+ signaling and GPR55-mediated ERK1/2 phosphorylation. CID 16020046 reduces wound healing in endothelial cells and is involved in the regulation of platelet function.
- GC44217 ML-184 GPR55 is a G protein-coupled receptor that is weakly activated by some cannabinoids (CBs) at nM concentrations but displays a 5- to 10-fold greater stimulation in response to 1 μM lysophosphatidylinositol (LPI).
- GC14026 ML-193 GPR55 antagonist
-
GC13513
O-1602
GPR55 cannabinoid receptor agonist
- GC16103 Oleylethanolamide Oleylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.
- GC17777 Palmitoylethanolamide GPR55 agonist
-
GC69771
PSB-SB-487
PSB-SB-487 is an effective GPR55 antagonist and CB2 agonist, with an IC50 of 0.113 µM for GPR55 and a Ki of 0.292 µM for human CB2. PSB-SB-487 can be used to study diabetes, Parkinson's disease, neuropathic pain, and cancer.